BiotechTV - News - TopPodcast.com

Latest Episodes:

Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic Apr 14, 2026

Show notes

Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an overview of programs targeting MRGPRX2, PTH1R, and a collaboration with Novo on obesity.

Raymond James Biotech Innovation Symposium: Raymond James analyst Chris Raymond shares his take on biotech and companies he covers Apr 14, 2026

Show notes

He discusses Tyra, Sionna, Alumis, Nuvalent, and Monopar.

Harbinger Health is announcing its emphasis on a new category of cancer screening tests today, RESOLVE, that are meant to be used upon the suspicion of cancer symptoms to speed diagnosis and treatment Apr 14, 2026

Show notes

CEO Ajit Singh describes the idea behind the new products, and highlights that $100M has been raised to fund the development of them.

Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC Apr 13, 2026

Show notes

CEO Cameron Turtle walks us through the data, shares his opinion on its translatability to part B of the current study, and tells us what else is ahead for Spyre.

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day. Apr 08, 2026

Show notes

He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multispecifics, and the state of discovery work today.

The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month Apr 08, 2026

Show notes

He describes how Stoke aims to up-regulate healthy genes in cases where diseases are caused by autosomal dominant haploinsufficiencies, like Dravet. He discusses the phase 1/2 data, a phase 3 that is scheduled to read out in 2027, and the regulatory history of the program.

Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way Apr 07, 2026

Show notes

He describes the multiple variables that factor in to designing new medicines with AI, how Iambic's platform has allowed it to shorten the time to get a medicine into the clinic versus traditional discovery work, and how he thinks AI will augment the work of human scientists.

Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies Apr 06, 2026

Show notes

He explains how Chai-2 works, and how it compares to other antibody building / binding AI models.

CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today Mar 31, 2026

Show notes

The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.

Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases Mar 27, 2026

Show notes

He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.